Age-related macular degeneration
The straight lines on this page should look straight.
If they bend, ripple, or fade in the middle, that is worth an eye appointment — not next month, but this week. MacularBrief explains age-related macular degeneration in plain language: what it does, what the warning signs are, and what the research actually supports.
- Written for readers over 50, at a text size you can actually read.
- Based on published research, including the National Eye Institute's AREDS and AREDS2 trials.
- Clear about what is not known and what no product can do.
The Amsler grid
A 30-second check you can do at home
- Put on your reading glasses, if you wear them.
- Hold the grid about 12 to 14 inches from your face, in good light.
- Cover one eye. With the other, look straight at the center dot.
- While staring at the dot, notice the rest of the grid without moving your eye.
- Repeat with the other eye. Most people are surprised the two do not match.
This site is for general information only. It is not medical advice. MacularBrief does not diagnose conditions, does not treat patients, and is not a substitute for an examination by a licensed eye care professional. Only a dilated eye exam can diagnose macular degeneration. Never delay seeking care, and never start, stop, or change a supplement or medication based on what you read here — talk to your doctor first. Read the full medical disclaimer.
The basics
What macular degeneration actually does
The macula is a small area at the center of the retina, roughly the size of this letter O. It handles the sharp, straight-ahead vision you use to read, drive, and recognize a face. Age-related macular degeneration damages that small area — and leaves the rest of your vision largely intact.
That distinction matters. AMD is the leading cause of severe vision loss in Americans over 50, but it does not cause total blindness. People with advanced AMD typically keep their peripheral vision and stay mobile. What they lose is the center of the picture.
Roughly 8 in 10 cases
Dry AMD
Small yellow deposits called drusen build up under the retina, and the light-sensing cells of the macula slowly thin out. This form usually progresses over years, not weeks.
Many people with early dry AMD have no symptoms at all and only learn about it during a routine dilated eye exam. In its advanced stage, called geographic atrophy, patches of the macula stop working altogether.
- Typical pace
- Gradual — often years between stages
- What doctors currently offer
- Monitoring, risk-factor management, and for some patients with intermediate disease, a specific supplement formula. Two injectable drugs approved in 2023 can slow geographic atrophy in selected patients, though neither restores vision that is already gone.
Roughly 1 to 2 in 10 cases
Wet AMD
Abnormal blood vessels grow beneath the retina and leak fluid or blood into the macula. This form is far less common, but it causes the majority of severe vision loss from AMD.
Wet AMD can move fast — noticeable change over days or weeks. Anyone with dry AMD can convert to the wet form, which is the reason home monitoring is worth the 30 seconds.
- Typical pace
- Rapid — days to weeks
- What doctors currently offer
- Anti-VEGF injections given in the eye by a retina specialist. These can stop the leaking, hold vision steady, and in some patients recover part of what was recently lost. They generally need to be repeated on a schedule.
What to watch for
Warning signs worth an appointment
Early AMD is often silent. When symptoms do appear, they show up in the center of your vision — and because your two eyes compensate for each other, they are easy to miss until you check one eye at a time.
Straight lines look wavy
Door frames, window blinds, lines of text, or tile grout appear bent or rippled. This is the sign that most often points to the wet form.
A blur or blank spot in the center
A smudged, dim, or empty patch sits in the middle of what you are looking at, while the edges stay clear.
You need much more light
Reading that was comfortable last year now requires a bright lamp aimed directly at the page, and adjusting to a dim room takes longer.
Faces are harder to recognize
You know someone by their voice, walk, or coat before you can make out their features across a room.
Colors seem washed out
Reds and greens look duller or less distinct than they used to, particularly with one eye covered.
Words drop out of a line
While reading, letters or whole words disappear or smear, and moving your eye slightly brings them back.
Do not wait on sudden change
A rapid increase in distortion, a new dark spot, or a noticeable drop in central vision over days should be treated as urgent. Call your eye doctor's office and say those words — sudden central vision change — rather than booking the next routine slot. If wet AMD is the cause, the window in which treatment protects the most vision is measured in days and weeks.
Who is affected
What raises the risk
Some of these you cannot change. One of them you can change more than any other, and it is the one most people underestimate.
- Age over 50Risk climbs steeply after 60 and again after 75. Fixed
- SmokingCurrent smokers carry several times the risk of people who never smoked. Risk falls after quitting. Can change
- Family historyA parent or sibling with AMD meaningfully raises your own risk. Fixed
- GeneticsSeveral gene variants are linked to AMD, though testing rarely changes what a doctor recommends today. Fixed
- Race and ancestryAMD is diagnosed more often in people of European descent. Fixed
- High blood pressure and heart diseaseCardiovascular health and retinal health track together. Can change
- Weight and dietDiets low in leafy greens and fish are associated with higher risk in observational studies. Can change
Separating claim from evidence
What the research supports — and what it does not
Vision supplements are marketed heavily to people over 50, and much of that marketing describes results the underlying research never showed. Here is the honest version.
The National Eye Institute ran two large trials, AREDS and AREDS2, testing a specific combination of nutrients in people who already had AMD. The findings were real, and they were also narrow. Almost every claim you will see in advertising stretches them.
| The claim | What the research found | Verdict |
|---|---|---|
| Slows progression to advanced AMD | In people who already had intermediate AMD in one or both eyes, or advanced AMD in one eye, the AREDS formula reduced the risk of progressing to advanced AMD by roughly a quarter over five years. | Supported |
| Prevents AMD in healthy eyes | The trials did not show benefit for people with no AMD or with only early AMD. Taking the formula as a preventive measure was not what the research tested or found. | Not supported |
| Restores or reverses vision already lost | No supplement in these trials recovered lost vision. Damage to the macula that has already occurred was not undone. | Not supported |
| Replaces the need for an eye doctor | Participants in both trials were followed with regular clinical exams throughout. Supplementation was studied alongside eye care, never instead of it. | Not supported |
| Any lutein product is equivalent | AREDS2 tested one defined formulation at defined doses. Products differ substantially in ingredients and amounts, and being sold in the same category does not make them comparable. | Not supported |
Two details that get left out of advertising
AREDS2 replaced beta-carotene with lutein and zeaxanthin after the original formula was linked to higher lung cancer risk in smokers and former smokers. If you have ever smoked, that substitution is not a footnote — it is the reason the newer formulation exists, and it is worth naming when you talk to your doctor.
The formula also contains a substantial dose of zinc, which can interact with certain medications and is not appropriate for everyone. Supplements are not automatically safe because they are sold without a prescription. Bring the actual bottle, or a photo of the label, to your next appointment and let your doctor decide whether it fits your situation.
Make the appointment count
Questions to bring to your eye exam
Appointments are short and it is easy to leave without the answers you came for. These are worth writing down beforehand.
- Do I have any signs of macular degeneration, and if so, is it early, intermediate, or advanced?
- Is it the dry form or the wet form, and is there any sign of conversion?
- Is my condition the same as last visit, or has it changed?
- Based on my stage specifically, would an AREDS2 formulation help me — or am I outside the group it was shown to benefit?
- Does the zinc in that formula interact with anything I already take? Here is my medication list.
- Should I be checking an Amsler grid at home, and how often?
- What specific change should make me call you right away rather than wait for my next visit?
- How often do you want to see me from here?
- If my vision does decline, what low-vision aids or services would you recommend, and when should I start looking into them?
- Is there anything in my family history or lifestyle I should be acting on now?
Print this list, or photograph it with your phone, and hand it to the doctor at the start of the visit rather than the end. Bringing someone with you to take notes is not overkill — most people retain only a fraction of what is said in a medical appointment.
Independent sources
Where to read further
These organizations publish patient information at no cost and do not sell treatments. If anything on this page matters to you, they are the next place to go.
National Eye Institute
Part of the National Institutes of Health. Publishes the AREDS and AREDS2 findings and plain-language guides to AMD.
nei.nih.govAmerican Academy of Ophthalmology
The professional body for U.S. eye physicians and surgeons. Patient guides and a directory to find an ophthalmologist near you.
aao.org/eye-healthMedicare
Coverage details for eye exams, including annual exams for beneficiaries at high risk of certain eye conditions.
medicare.govBrightFocus Foundation
Nonprofit funding macular degeneration research, with a free patient information line and printed materials.
brightfocus.org